Mutations in DRP2 (OMIM #300052) encoding dystrophin-related protein 2, a 957 amino acid protein, were identified in a single patient with X-linked Charcot-Marie-Tooth (CMT) disease and are associated with familial autism.1,2 DRP2 is predominantly expressed in the brain and spinal cord and functionally interacts with periaxin (PRX, OMIM #605725), a known causative CMT gene (OMIM #614895 and #145900), in the PRX-DRP2-dystroglycan (PDG) complex.3 The PDG complex supports and maintains Cajal bands, which are cytoplasmic extensions that run along the length of myelinated axons and are required for establishing a proper internodal length.4,–,6
A nonsense DRP2 c.805C>T (Q269X) mutation was found in a patient with sensorimotor neuropathy, with intermediate conduction velocities and absence of Cajal bands within dermal nerves.1 Here, we report another patient with a novel nonsense mutation in DRP2 with sensorimotor polyneuropathy and histologic myelin abnormalities. This report extends the known mutation spectrum of DRP2 and provides further evidence of its association with inherited neuropathy.
Case report
The index patient is a 42-year-old man who developed fatigue, numbness and tingling in his fingers and toes, and headaches at the age of 18. Over time, he developed patchy burning in his extremities, intermittent numbness in his face, heat intolerance, and excessive sweating. There was no family history of neuropathy. Nerve conduction studies at the age of 33 demonstrated mildly slowed conduction velocities and prolonged F-wave latencies in the lower extremities. A left sural nerve biopsy showed fibers with tomaculae, thinly myelinated fibers, and a small focus of perivascular epineurial inflammation. A lumbar puncture was performed and showed normal CSF protein levels and cell counts. Testing for diabetes mellitus, Sjogren syndrome, HIV, and Lyme disease was negative, and hexosaminidase A and α-galactosidase levels were normal. Testing for mutations of PMP22, MFN2, and GBJ1 was negative.
At the age of 40, examination showed normal cognition, cranial nerves, muscle bulk, tone, and strength. He was able to walk on his heels and toes. Deep tendon reflexes were mildly reduced at the ankles (1+) but were otherwise normal. There was multimodal distal sensory loss with light touch, pinprick, and temperature reduced in the lower extremities to the mid-shins and in the upper extremities to the mid-forearms. Joint position sense was preserved, and vibration sense was normal except for a mild reduction at the left first toe. Augmented Romberg (feet in tandem position) was positive. Repeat electrophysiology revealed evidence of lower extremity demyelinating neuropathy with nonuniformly reduced conduction velocities of the bilateral peroneal motor nerves (right 31 m/s, left 22 m/s, normal ≥40 m/s) with normal distal latencies, partial motor conduction block in the bilateral peroneal motor nerves recorded at the extensor digitorum brevis muscle ([ankle vs fibular head stimulation]: right [2.5 vs 0.9 mV], left [1.5 vs 0.1 mV]), and markedly prolonged lower extremity F-wave latencies (right tibial 82 milliseconds, left peroneal 73 milliseconds, normal <56 milliseconds). Upper extremity testing showed a normal conduction velocity in the median motor nerve and a slightly reduced velocity (46 m/s, normal ≥50 m/s) in the ulnar motor nerve. Skin biopsy and autonomic testing were normal.
Electron microscopy of his sural nerve revealed a mild reduction in the density of large myelinated and unmyelinated axons as well as prominent variability in myelin thickness with many thinly myelinated fibers and some abnormally thick myelinated fibers (figure). We observed many fibers with delamination of myelin, occasional Cajal bands, rare tomaculae, rare active demyelination, and rare miniature onion bulbs indicative of prior demyelination and attempted remyelination. Whole-exome sequencing revealed a hemizygous c.1039C>T, p.Q347X variant in DRP2 that creates a premature stop codon. This variant is not present in the database of the Exome Aggregation Consortium (exac.broadinstitute.org, September 2016). His unaffected mother is a carrier for the change.
(A and B) Sural nerve biopsy shows variability in myelin thickness, with some fibers exhibiting thicker myelin sheets relative to axon diameter (thin arrows) and many others harboring thin myelin (thick arrowheads). Many of the thicker myelinated fibers showed delamination. (C and D) Higher power view of myelin thickness variability. Thickly myelinated axon (thin arrow) shows a small tomacula. (E) Miniature onion bulb formation. (F) A myelinated axon (thin arrow) undergoing demyelination. Scale bars denote 10 μm in A and B, 5 μm in C and D, and 2 μm in E and F.
Discussion
In this report, we present a patient with early adult-onset sensorimotor neuropathy with biopsy-proven myelination abnormalities and a likely pathogenic hemizygous mutation in the X-linked gene DRP2. This mutation produces a premature stop codon and is expected to lead to a loss of functional protein and likely a complete absence of DRP2 in men.1,7 The biopsy findings are reminiscent of the previously reported patient with DRP2 mutation who displayed the absence of Cajal bands in dermal nerves, and to the histologic features of Drp2-null mice, which show disrupted appositions of Cajal bands, focal hypermyelination, demyelination, and tomacula-like formations.1,8 Similarly, Prx-null mice also show the absence of Cajal bands, shortened internodal length, and reduced conduction velocities.9 It is important that the patient reported here had features of both developmental dysmyelination as well as nonuniform demyelination, the latter of which was not present in the previously reported patient with DRP2 mutation. This report provides further evidence linking truncating DRP2 mutations with demyelinating neuropathy and suggests that DRP2 variants should be considered when evaluating patients suspected of inherited neuropathy.
Author contributions
Dr. Roda: drafting and revision of the manuscript and analysis of patient data. Dr. McCray: critical analysis and revision of the manuscript. Dr. Klein: patient care and critical analysis and revision of the manuscript. Dr. Hoke: patient care, electron microscopy, and critical analysis and revision of the manuscript.
Study funding
No targeted funding reported.
Disclosure
R. Roda and McCray have received research support from the NIH. B. C. Klein serves on the CMTA Research and Therapeutics board (a nonprofit patient support group); serves on the editorial board of Neurology®; and receives research support from a Mayo Clinic research grant. Dr. Hoke serves on the scientific advisory board of the Foundation for Peripheral Neuropathy; serves on the editorial boards of Experimental Neurology and Annals of Clinical Translational Neurology; holds patents for Use of ethoxyquin to prevent neuropathy and for Electro-spun fiber mesh to help nerve regeneration; is an employee of Johns Hopkins University; has served as a consultant for Neurocrine Inc.; has received research support from the NIH, the Foundation for Peripheral Neuropathy, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; gave expert testimony on GBS for National Vaccine Injury Program, and gave expert testimony on peripheral neuropathy for Arnold & Porter Kaye Scholer LLP. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.
The Article Processing Charge was funded by the authors.
- Received August 8, 2017.
- Accepted in final form December 12, 2017.
- Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
